Details of the BTS
| General Information of Binding Target of SBP (BTS) (ID: ST00091) | ||||||
|---|---|---|---|---|---|---|
| BTS Name |
B-lymphocyte antigen CD19
|
|||||
| Synonyms |
B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12; CD antigen CD19
|
|||||
| BTS Type |
Protein
|
|||||
| Gene Name |
CD19
|
|||||
| Organism |
Homo sapiens (Human)
|
|||||
| Function |
Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores Is not required for early steps during B cell differentiation in the blood marrow Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge
|
|||||
| UniProt ID | ||||||
| UniProt Entry | ||||||
| Gene ID | ||||||
| Sequence |
MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKP
FLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGE LFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSL NQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMW VMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYL IFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSG LGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEF YENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLS PHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGP DPAWGGGGRMGTWSTR |
|||||
| Sequence Length |
556
|
|||||
| Synthetic Binding Protein (SBP) Targeting This BTS |
|---|
| SBP Name | Highest Status | Mechanism | Affinity | Application | Details | Ref |
|---|---|---|---|---|---|---|
| BiTE AMG-562 | Phase I | Modulator | N.A. | B-cell non-hodgkin lymphoma [ICD-11: 2B33.5]; Follicular lymphoma [ICD-11: 2A80]; Mantle cell lymphoma [ICD-11: 2A85.5] | [1], [2] | |
| BiTE anti-CD19/CD3 AMG103 | Research | Binder | N.A. | Cancers [ICD-11: 2D4Z] | [3] | |
| BiTE Blinatumomab | Marketed | Binder | N.A. | Burkitt-like lymphoma with 11q aberration [ICD-11: XH8NN2] | [4], [5], [6] | |
| DART Duvortuxizumab | Phase I; Discontinued | Binder | N.A. | B-cell hematological malignancies [ICD-11: 2B33.Y] | [7] | |
| References |
|---|